Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
暂无分享,去创建一个
J. Farrar | Pham Van Toi | Jeremy Farrar | T. Pouplin | Thomas Pouplin | Pham Nguyen Phuong | Julie Nguyen Pouplin | Julie Nguyen Pouplin
[1] D. Gibb,et al. Young HIV-Infected Children and Their Adult Caregivers Prefer Tablets to Syrup Antiretroviral Medications in Africa , 2012, PloS one.
[2] A. Diacon,et al. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. , 2011, Tuberculosis.
[3] S. Graham. Mini-symposium : Childhood TB in 2010 Treatment of paediatric TB : revised WHO guidelines , 2010 .
[4] S. Swaminathan,et al. Pediatric tuberculosis: global overview and challenges. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] U. Wahn,et al. Rifampicin serum levels in childhood tuberculosis. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[6] K. Karlage,et al. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. , 2009, Journal of managed care pharmacy : JMCP.
[7] P. Donald. The assessment of new anti-tuberculosis drugs for a paediatric indication. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] S. Ward,et al. Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.
[9] R. Gie,et al. Management of the child with cough or difficult breathing. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[10] P. V. van Helden,et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis , 2005, Archives of Disease in Childhood.
[11] R. Shankar,et al. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. , 2001, International journal of pharmaceutics.
[12] P. B. Fourie,et al. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[13] C. T. Viswanathan,et al. Pharmacokinetics of rifampin in children. II. Oral bioavailability. , 1986, Therapeutic drug monitoring.